AI Article Synopsis
- There is currently no standardized treatment for Riehl's melanosis, a skin condition that can be difficult to manage effectively.
- This study aimed to compare the effectiveness and safety of combining oral tranexamic acid (TXA) with intense pulsed light (IPL) therapy versus using TXA alone in 28 patients with the condition.
- Results showed that the combination therapy significantly improved skin pigmentation and patient satisfaction without increased side effects, suggesting it's a safe and effective treatment approach.
Article Abstract
Background: There is no standardized and effective treatment modality for Riehl's melanosis.
Aims: To compare the efficacy and safety of oral tranexamic acid (TXA) combined with intense pulsed light (IPL) versus TXA alone in the treatment of refractory Riehl's melanosis.
Methods: A prospective study of 28 subjects with refractory Riehl's melanosis and Fitzpatrick Skin Types III or IV was conducted. All subjects received oral TXA 500 mg daily and 11 of them were treated in combination with monthly IPL therapy for 6 months. The primary outcome measure was mean melanin index (MI), erythema index (EI) and acquired dermal macular hyperpigmentation area and severity index (DPASI). The Physician Global Assessment (PGA) and patient satisfaction scale were documented.
Results: After treatment, DPASI, mean MI, and EI were significantly reduced in both groups. The group treated with combination therapy showed better improvement according to MI (p = 0.0032) and DPASI (p = 0.00468). PGA and patient satisfaction scale showed superior efficacy in the combination group. No significant difference was observed in treatment-related side effects.
Conclusion: The combination of oral TXA and IPL proves to be a safe and satisfactory treatment strategy for refractory Riehl's melanosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jocd.16257 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of the combination of oral tranexamic acid and intense pulsed light versus oral tranexamic acid alone in the treatment of refractory Riehl's melanosis: A prospective, comparative study.
J Cosmet Dermatol
June 2024
Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, PR China.
Article Synopsis
- There is currently no standardized treatment for Riehl's melanosis, a skin condition that can be difficult to manage effectively.
- This study aimed to compare the effectiveness and safety of combining oral tranexamic acid (TXA) with intense pulsed light (IPL) therapy versus using TXA alone in 28 patients with the condition.
- Results showed that the combination therapy significantly improved skin pigmentation and patient satisfaction without increased side effects, suggesting it's a safe and effective treatment approach.
Oral tranexamic acid in the treatment of hyperpigmentation disorder beyond melasma: A review.
J Cosmet Dermatol
April 2023
Al- Thaghar general hospital, Ministry of health, Jeddah, Saudi Arabia.
Article Synopsis
- Tranexamic acid is a synthetic amino acid derivative that helps prevent bleeding and is used to treat various hyperpigmentation disorders, including melasma, with demonstrated effectiveness.
- A literature review explored the use of tranexamic acid for conditions like postinflammatory hyperpigmentation, lichen planus pigmentosus, ashy dermatosis, and Riehl melanosis with varying doses and durations.
- While tranexamic acid shows promise as a treatment for hyperpigmentation disorders unresponsive to topical treatments, further robust studies are needed to validate its efficacy across different conditions.
Therapeutic Effects of New Pulsed-Type Microneedling Radiofrequency for Refractory Facial Pigmentary Disorders.
Dermatol Surg
March 2022
Department of Dermatology, Hanyang University College of Medicine, Seoul, Korea.
Article Synopsis
- A new radiofrequency (RF) device was introduced to treat facial pigmentary disorders, showing promising outcomes.
- In a study with 44 patients suffering from melasma or Riehl melanosis, significant clinical improvements were observed after five RF treatments, with various assessments confirming reduced pigmentation and skin health improvements.
- Histopathological analysis indicated a decrease in melanin and related components, while no serious side effects were reported, suggesting that pulsed-type microneedling RF could be an effective treatment option for these skin conditions.
Pan-Cancer Efficacy of Vemurafenib in -Mutant Non-Melanoma Cancers.
Cancer Discov
May 2020
Memorial Sloan Kettering Cancer Center, New York, New York.
mutations occur in a wide range of tumor types, and RAF inhibition has become standard in several of these cancers. Despite this progress, mutations have historically been considered a clear demonstration of tumor lineage context-dependent oncogene addiction, based predominantly on the insensitivity to RAF inhibition in colorectal cancer. However, the true broader activity of RAF inhibition pan-cancer remains incompletely understood.
View Article and Find Full Text PDFPhase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia.
Clin Epigenetics
December 2019
KiTZ Clinical Trial Unit, Hopp Children's Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany.
Background: Until today, adult and pediatric clinical trials investigating single-agent or combinatorial HDAC inhibitors including vorinostat in solid tumors have largely failed to demonstrate efficacy. These results may in part be explained by data from preclinical models showing significant activity only at higher concentrations compared to those achieved with current dosing regimens. In the current pediatric trial, we applied an intra-patient dose escalation design.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!